Clinical impact of chromosomal aberrations in multiple myeloma

Journal of Internal Medicine

Volumn 269, Issue 2, 2011, Pages 137-147

  Nahi, H ^a   Sutlu, T ^a   Jansson, M ^a   Alici, E ^a   Gahrton, G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bortezomib; Chromosomal aberrations; Lenalidomide; Multiple myeloma; Stem cell transplantation; Thalidomide

Indexed keywords

BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISOLONE; THALIDOMIDE; VINCRISTINE;

ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CHROMOSOME TRANSLOCATION 8; CLINICAL TRIAL; DIPLOIDY; DRUG EFFECT; DRUG EFFICACY; GENE DELETION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHROMOSOME ABERRATIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 78651078746     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02324.x     Document Type: Review

References (100)

1. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380-90.
2. Barlogie B, Epstein J, Selvanayagam P, Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood 1989; 73: 865-79.
3. Liang W, Hopper JE, Rowley JD. Karyotypic abnormalities and clinical aspects of patients with multiple myeloma and related paraproteinemic disorders. Cancer 1979; 44: 630-44.
4. Gahrton G, Zech L, Nillsson K, Lonnqvist B, Carlstrom A. 2 translocations, t(11;14) and t(1;6), in a patient with plasma cell leukaemia and 2 populations of plasma cells. Scand J Haematol 1980; 24: 42-6.
5. Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002; 56: 223-34.
6. Avet-Loiseau H, Attal M, Moreau P et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-95.
7. Landgren O, Kyle RA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-7.
8. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 1995; 82: 41-9.
9. Hanamura I, Stewart JP, Huang Y et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108: 1724-32.
10. Cremer FW, Bila J, Buck I et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer 2005; 44: 194-203.
11. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 91: 1732-41.
12. Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005; 10(Suppl 1): 117-26.
13. Shaughnessy JD Jr, Barlogie B. Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 77-80.
14. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 2003; 4: 251-6.
15. Zhan F, Colla S, Wu X et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood 2007; 109: 4995-5001.
16. Chang H, Jiang N, Jiang H et al. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in multiple myeloma. Haematologica 2010; 95: 1542-7.
17. Avet-Loiseau H, Andree-Ashley LE, Moore D III et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosom Cancer 1997; 19: 124-33.
18. Debes-Marun CS, Dewald GW, Bryant S et al. Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003; 17: 427-36.
19. Gutierrez NC, Garcia JL, Hernandez JM et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104: 2661-6.
20. Leone PE, Walker BA, Jenner MW et al. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res 2008; 14: 6033-41.
21. Poulsen TS, Silahtaroglu AN, Gisselo CG, Tommerup N, Johnsen HE. Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes. Leukemia 2002; 16: 2148-55.
22. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004; 104: 607-18.
23. Fonseca R, Blood E, Rue M et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569-75.
24. Chesi M, Nardini E, Brents LA et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997; 16: 260-4.
25. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
26. Bisping G, Wenning D, Kropff M et al. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma. Clin Cancer Res 2009; 15: 520-31.
27. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 1998; 92: 3025-34.
28. Lauring J, Abukhdeir AM, Konishi H et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008; 111: 856-64.
29. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 2003; 101: 2374-6.
30. Chesi M, Bergsagel PL, Shonukan OO et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457-63.
31. Kataoka K, Nishizawa M, Kawai S. Structure-function analysis of the maf oncogene product, a member of the b-Zip protein family. J Virol 1993; 67: 2133-41.
32. Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126: 355-63.
33. Stralen E, Leguit RJ, Begthel H et al. MafB oncoprotein detected by immunohistochemistry as a highly sensitive and specific marker for the prognostic unfavorable t(14;20) (q32;q12) in multiple myeloma patients. Leukemia 2009; 23: 801-3.
34. Ross FM, Chiecchio L, Dagrada G et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long term stable disease in MGUS. Haematologica 2010; 95: 1221-5.
35. Pruneri G, Fabris S, Baldini L et al. Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14). Am J Pathol 2000; 156: 1505-13.
36. Moreau P, Facon T, Leleu X et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-83.
37. Gertz MA, Lacy MQ, Dispenzieri A et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-40.
38. Avet-Loiseau H, Garand R, Lode L, Harousseau JL, Bataille R. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003; 101: 1570-1.
39. Fonseca R, Blood EA, Oken MM et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 2002; 99: 3735-41.
40. Shaughnessy J Jr, Gabrea A, Qi Y et al. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 2001; 98: 217-23.
41. Sonoki T, Harder L, Horsman DE et al. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 2001; 98: 2837-44.
42. Martinez-Climent JA, Vizcarra E, Sanchez D et al. Loss of a novel tumor suppressor gene locus at chromosome 8p is associated with leukemic mantle cell lymphoma. Blood 2001; 98: 3479-82.
43. Rubio-Moscardo F, Blesa D, Mestre C et al. Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. Blood 2005; 106: 3214-22.
44. Sutlu T, Alici E, Jansson M et al. The prognostic significance of 8p21 deletion in multiple myeloma. Br J Haematol 2009; 144: 266-8.
45. Neben K, Jauch A, Bertsch U et al. Combining chromosomal aberrations t(4;14) and del(17p13) with ISS allows a stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010; 95: 1150-7.
46. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817-24.
47. Takeda K, Smyth MJ, Cretney E et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002; 195: 161-9.
48. Anguiano A, Tuchman SA, Acharya C et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009; 27: 4197-203.
49. Fabris S, Storlazzi CT, Baldini L et al. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Genes Chromosom Cancer 2003; 37: 261-9.
50. Avet-Loiseau H, Gerson F, Magrangeas F, Minvielle S, Harousseau JL, Bataille R. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98: 3082-6.
51. Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R. Cellular DNA content as a marker of human multiple myeloma. Blood 1980; 55: 403-8.
52. Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K. Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 1985; 66: 338-41.
53. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 2001; 98: 2229-38.
54. Fassas AB, Spencer T, Sawyer J et al. Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br J Haematol 2002; 118: 1041-7.
55. Chng WJ, Kumar S, Vanwier S et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-9.
56. Chng WJ, Santana-Davila R, Van Wier SA et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20: 807-13.
57. Avet-Loiseau H, Li C, Magrangeas F et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27: 4585-90.
58. Tricot G, Barlogie B, Jagannath S et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-6.
59. Chang H, Sloan S, Li D et al. The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 2004; 125: 64-8.
60. Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105: 358-60.
61. Gutierrez NC, Castellanos MV, Martin ML et al. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007; 21: 143-50.
62. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345-57.
63. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-23.
64. Nahi H, Lehmann S, Bengtzen S et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma 2008; 49: 508-16.
65. Schilling G, Hansen T, Shimoni A et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22: 1250-5.
66. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7.
67. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83.
68. Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-63.
69. Attal M, Harousseau JL, Facon T et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-502.
70. Rosinol L, Oriol A, Mateos MV et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J Clin Oncol 2007; 25: 4452-8.
71. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-505.
72. Barlogie B, Anaissie E, van Rhee F et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-85.
73. Pineda-Roman M, Zangari M, Haessler J et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140: 625-34.
74. Avet-Loiseau H, Leleu X, Roussel M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4.
75. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 2008; 93: 124-7.
76. Koreth J, Cutler CS, Djulbegovic B et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183-96.
77. Mellqvist UHWJ, Gimsing P, Hjertner O et al. Improved response rate with bortezomib consolidation after high dose melphalan: first results of a Nordic Myeloma Study Group randomized phase III trial. Blood 2010; 114: 2221. ASH abstract 530.
78. Attal MCC, Marit G, Caillot D et al. Lenalidomide maintenance after transplantation for myeloma. J Clin Oncol 2010; 28: 15. Abstract 8010.
79. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-16.
80. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-22.
81. Giralt S, Aleman A, Anagnostopoulos A et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-73.
82. Crawley C, Lalancette M, Szydlo R et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532-9.
83. Gahrton HG, Iacobelli S, Hegenbart U et al. Tandem Autologous(ASCT)/Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT. Blood 2009; 114: 22. Abstract 52.
84. Kroger N, Sayer HG, Schwerdtfeger R et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-24.
85. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-60.
86. Jagannath S, Richardson PG, Sonneveld P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007; 21: 151-7.
87. Sagaster V, Ludwig H, Kaufmann H et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007; 21: 164-8.
88. San Miguel JF, Schlag R, Khuageva NK et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-17.
89. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-94.
90. Morgan GJ, Davies FE, Gregory WM et al. The addition of thalidomide to the induction treatment of newly presenting myeloma patients increases the CR rate which is likely to translate into improved PFS and OS. Blood 2009;114: 194. Abstract 352.
91. Reece D, Song KW, Fu T et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114: 522-5.
92. Durie BG. Cellular and molecular genetic features of myeloma and related disorders. Hematol Oncol Clin North Am 1992; 6: 463-77.
93. Facon T, Lai JL, Nataf E et al. Improved cytogenetic analysis of bone marrow plasma cells after cytokine stimulation in multiple myeloma: a report on 46 patients. Br J Haematol 1993; 84: 743-5.
94. Hernandez JM, Gutierrez NC, Almeida J et al. IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. Br J Haematol 1998; 103: 163-7.
95. Drach J, Schuster J, Nowotny H et al. Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 1995; 55: 3854-9.
96. Paul E, Sutlu T, Deneberg S et al. Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation. Oncol Rep 2009; 22: 137-42.
97. Fonseca R, Van Wier SA, Chng WJ et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034-40.
98. Chang H, Qi X, Jiang A, Xu W, Young T, Reece D. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 2010; 45: 117-21.
99. Avet-Loiseau H, Facon T, Grosbois B et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99: 2185-91.
100. Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.